低分子药物研发市场，各治疗领域，流程/不同阶段，各地区- 规模，占有率，展望，机会分析，2022年～2028年

市场力学

慢性病的高发病率、对小分子药物的需求增加、对小分子药物发现的日益关注、合同组织数量的增加以及研发活动的增加，预计将推动全球小分子药物发现市场的增长。

本调查的主要特征

• 本报告提供以2021年为基准年的预测期间（2022-2030 年）之全球低分子药物研发市场的市场规模和復合年增长率（CAGR %）相关的详细分析。
• 并阐明不同部门市场的潜在收入机会，说明该市场具有魅力的投资主张矩阵。
• 同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
• 并基于企业亮点，各类型投资组合、主要焦点、财务业绩和市场策略等参数，介绍全球低分子药物研发市场的主要参与者之企业简介。
• 藉由该报告提供的洞察，将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
• 全球低分子药物研发市场报告配合该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者可以透过全球低分子药物研发市场用于分析的各种战略矩阵来帮助他们更容易做下决策。

目录

第1章 调查目的与前提条件

• 调查目的
• 前提条件
• 简称的说明

第2章 市场展望

• 报告内容
  • 市场定义和范围
• 摘要整理
  • 市场概述:各治疗领域
  • 市场概述:流程/不同阶段
  • 市场概述:各地区
• 连贯机遇地图(COM)

第3章 市场动态，法规，及趋势的分析

• 市场动态
  • 全球慢性病患病率上升
  • 严格的法规和高昂的药物开发成本
  • 全球对小分子药物的需求上升
• 影响分析
• 主要的焦点
• 法规方案
• 产品上市/核准
• PEST分析
• PORTER的分析
• 合併·收购情景

第4章 低分子药物研发的全球市场-冠状病毒(COVID-19)疫情的影响

• COVID-19流行病学的特征
• 供给面和需求面的分析
• 经济衝击

第5章 低分子药物研发的全球市场，各治疗领域，2017年～2028年

• 肿瘤学
• 中枢神经系统
• 循环系统系
• 呼吸系统
• 代谢异常
• 消化器官
• 其他治疗领域

第6章 低分子药物研发的全球市场(流程/不同阶段):2017年～2028年

• 目标ID/验证
• 命中生成和选择
• 领导的鑑定
• 领导的最佳化

第7章 低分子药物研发的全球市场，各地区，2017年～2028年

• 北美
• 欧洲
• 亚太地区
• 南美
• 中东·非洲
• 全球其他地区

第8章 竞争情形

• Pfizer Inc.
• Novartis
• Teva Pharmaceuticals
• Merck KgaA
• Johnson & Johnson
• GlaxoSmithKline PLC
• Gilead Sciences Inc.
• AstraZeneca
• Immunocure Inc.
• Acacia Pharma Gr
• 4SC AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• 21st Century Therapeutics Inc.
• Takeda Pharmaceutical Industries Ltd.

第9章 章节

• 调查手法
• 关于出版社

Small molecule drugs have represented some of the crucial blockbusters in the history of the pharmaceutical industry. Defined as any organic compound with low molecular weight, small molecule drugs have some distinct advantages as therapeutics. Small molecule drugs capable of modulating biochemical processes to diagnose, treat, and prevent diseases. Small molecule drugs are the mainstay of medicine, representing around 90 percent of all approved medicines and 75 percent of all new medicines approved in the U.S. in 2020.

Market Dynamics:

High prevalence of chronic diseases, increase in demand for small molecule drugs, rise in focus on small molecule drug discovery, increasing number of contract organizations, and increase in research and development activities are some major factors expected to augment the growth of the global small molecule drug discovery market.

In July 2022, RxCelerate revealed details of a new small molecule discovery platform, named RxNfinity, which leverages machine learning, in silico structure modeling and combinatorial chemistry in a novel workflow that offers significant advantages over the current generation of tools to identify small molecule drugs against a wide range of protein targets.

In July 2022, Dotmatics announced the release of its Small Molecule Drug Discovery Solution, an integrated scientific research and development platform with pre-configured workflows and expanded data management capabilities. The new solution will help companies innovate more easily by leveraging best practices derived from Dotmatics' 15+ years of experience supporting small molecule drug discovery.

Key features of the study:

• This report provides in-depth analysis of the global small molecule drug discovery market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global small molecule drug discovery market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Teva Pharmaceuticals, Merck KgaA, Johnson & Johnson, GlaxoSmithKline PLC, Gilead Sciences Inc., AstraZeneca, Immunocure Inc., Acacia Pharma Gr, 4SC AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, 21st Century Therapeutics, Novartis, Pfizer Inc., and Takeda Pharmaceutical Industries Ltd., among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global small molecule drug discovery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global small molecule drug discovery market.

Detailed Segmentation:

• Global Small Molecule Drug Discovery Market, By Therapeutic Area:
  • Oncology
  • Central Nervous System
  • Cardiovascular
  • Respiratory
  • Metabolic Disorders
  • Gastrointestinal
  • Other Therapeutic Areas
• Global Small Molecule Drug Discovery Market, By Process/Phase:
  • Target ID/Validation
  • Hit Generation and Selection
  • Lead Identification
  • Lead Optimization
• Global Small Molecule Drug Discovery Market, By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa
• Company Profiles:
  • Teva Pharmaceuticals
  • Merck KgaA
  • Johnson & Johnson
  • GlaxoSmithKline PLC
  • Gilead Sciences Inc.
  • AstraZeneca
  • Immunocure Inc.
  • Acacia Pharma Gr
  • 4SC AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • 21st Century Therapeutics Inc.
  • Novartis
  • Pfizer Inc.
  • Takeda Pharmaceutical Industries Ltd.

Table of Contents:

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Therapeutic Area
  • Market Snapshot, By Process/Phase
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of chronic diseases worldwide
  • Stringent regulations and high cost of drug development
  • Rise in demand for small molecule drugs worldwide
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Small Molecule Drug Discovery Market - Impact of Coronavirus (Covid-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Small Molecule Drug Discovery Market, By Therapeutic Area, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Central Nervous System
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Cardiovascular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Respiratory
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Metabolic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Gastrointestinal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Other Therapeutic Areas
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global Small Molecule Drug Discovery Market, By Process/Phase, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Target ID/Validation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Hit Generation and Selection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Lead Identification
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
• Lead Optimization
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

7. Global Small Molecule Drug Discovery Market, By Geography, 2017-2028, (US$ Mn)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Middle East and Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
• Rest of World
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

8. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck KgaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gilead Sciences Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Immunocure Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Acacia Pharma Gr
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• 4SC AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boehringer Ingelheim GmbH
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• 21st Century Therapeutics Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

9. Section

• Research Methodology
• About us